Abivax to present seven abstracts highlighting Obefazimod clinical data at ECCO 2025
Abivax SA, a clinical-stage biotechnology company developing innovative therapies to address chronic inflammatory diseases, today announced that seven scientific abstracts on its lead drug candidate, obefazimod, [an investigational,… read more.
